With Targets Of INR 1000 Crore, Aimil Pharmaceuticals Sets To Go Global
Aimil Pharmaceuticals is a well known name for herbal health products; as a leading manufacturer it is gearing up to fulfil the growing demands for Ayurveda products in the post pandemic reality. It was established with the aim of taking the legacy of Ayurveda ahead scientifically in 1984. It aims to improve quality of life amidst the ongoing health crisis by revolutionising Ayurvedic formulas.
Taking the upward swing Aimil Pharmaceuticals is all set to go global by entering the international markets in the first quarter of 2022. The company that has already strengthened its presence in the country will be launching its products across United Kingdom, Europe, CIS countries and Africa by expanding its digital as well as offline presence with its presence at drug stores, pharmacies and ethnic Indian stores in these markets. It is eyeing to increase its field strength to 2500 within the next five years and achieve INR 1000 Crore business in India and internationally as well.
K.K. Sharma, Chairman and MD, Aimil Pharmaceuticals said, "Today we are known in the medical industry for its quality herbal health products and has become the leading health contributor to the society by promoting a broad range of Ayurvedic products in different dosage forms. We are committed to the motto of health restoration and supplementation and we are providing not only qualitative but innovative healthcare products by concepts. We believe this is the most opportune time to take India's medical legacy before the world for better global health.”
The world is a different place now, the opportunities in Ayurvedic healthcare are huge especially after the pandemic that has made people across the globe realise the power and worth of herbal products. Currently, the global herbal supplements market has reached a value of US$ 6.3 billion and with a projected Compound Annual Growth Rate (CAGR) of 6.8% during 2021-2026.
The Covid pandemic had a significant impact on the healthcare system. Consumer attitudes changed dramatically in the aftermath of the pandemic and there has been a significant increase in demand for immunity and wellness products. Given this, the Ministry of AYUSH recommended the formula for Ayush Kwath, an herbal immunity enhancer. It must be noted that Aimil Pharmaceuticals manufactured and promoted Ayush Kwath at larger scale and also based on the customer feedback, it developed and launched its own proprietary product Amynity Plus, a multi system immune defence in the dosage form of liquid and drops. Amynity plus is enriched with herbal extracts and essential oils that primarily supports the respiratory system thereby sufficing the need for oxygen.
Taking a step ahead in the coming year, Aimil will focus on its top 5 brands including Neeri for UTI and kidney stone, Neeri KFT for chronic kidney diseases, BGR-34 for diabetes, Amlycure DS for liver health, Amycordial for Polycystic Ovarian Disease (PCOD) and female wellness and many others.
Aimil is working to make itself distinct from its competitors by filling the vacuum, doing the gap analysis in medical treatment patterns and productive health solutions. The products are designed and developed for the expected therapeutic efficacy considering basic factors of ancient Ayurvedic principles as well as advanced scientific parameters for consistent and optimal medicinal benefits with safety in patients. The company has also been recipient of three national awards from the Government of India and has also technically collaborated with institutes like Defence Research and Development Organisation (DRDO) and Council of Scientific and Industrial Research (CSIR).